ArticleCell communication and signaling : CCS2026
Glutamate accumulation in myelofibrosis microenvironment rewires mesenchymal stromal cells metabolic and epigenetic profiles.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by bone marrow (BM) fibrosis, osteosclerosis, and a proinflammatory tumor microenvironment (TME). The interplay between malignant hematopoietic stem cells and mesenchymal stromal cells (MSCs) drives disease progression. Although glutamate has been implicated in various cancers, its contribution to MF pathogenesis remains unclear.
methodsHigh-performance liquid chromatography (HPLC) profiling was performed on sera from MF patients and healthy controls (HCs) to identify alterations in amino acid abundance. The proteomic profiles of MF- and HC-derived MSCs were assessed by mass spectrometry. Functional assays in glutamate- and fumarate-treated MSCs were used to investigate metabolic, epigenetic, and phenotypic changes by HPLC, real-time PCR, flow cytometry, immunofluorescence, and Azan-Mallory staining. The therapeutic potential of metabotropic glutamate receptor 5 (mGluR5) inhibition was evaluated using in vitro and in vivo models.
resultsGlutamate emerged as the most enriched amino acid in MF sera. In MSCs, glutamate supplementation induced intracellular fumarate accumulation, mediated by increased expression of α-ketoglutarate dehydrogenase components and downregulation of fumarate hydratase activity. Fumarate treatment recapitulated an upregulation of oxidative phosphorylation, also enhancing mitochondrial ROS. Both fumarate and glutamate induced epigenetic remodeling, as shown by accumulation of 5-methylcytosine (5mC) and H3K36me2, which was also confirmed in primary MF-MSCs. Glutamate and fumarate induced a senescent phenotype in MSCs, characterized by increased β-galactosidase activity, oxidative stress and SASP-related genes induction. Both metabolites also promoted collagen deposition, supporting their involvement in fibrotic remodeling. Notably, selective inhibition of metabotropic glutamate receptor 5 (mGluR5) by UBP310 or UBP296 attenuated glutamate-driven senescence, reduced fumarate-associated epigenetic changes and limited collagen deposition in vitro and in vivo, supporting a central role for glutamate signaling in stromal dysfunction and fibrotic niche remodeling.
conclusionThis study identifies glutamate as a key metabolic and signaling factor in MF microenvironment. Glutamate rewires MSC metabolism via fumarate accumulation, drives epigenetic reprogramming, and induces senescence and fibrotic transformation. Targeting mGluR5 may therefore represent a promising therapeutic strategy to mitigate MSC dysfunction and bone marrow fibrosis in MF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.